New combo therapy aims to shrink untreatable liver tumors
Disease control
Recruiting now
This study is for people with liver cancer that cannot be surgically removed or treated with ablation. It compares a standard treatment called cTACE with a newer approach using tiny radioactive beads (yttrium-90) alone or combined with immunotherapy drugs (camrelizumab and/or apa…
Phase: PHASE2 • Sponsor: GrandPharma (China) Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC